Osimertinib Recruiting Phase 2 Trials for Locally Advanced or Metastatic NSCLC Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03414814Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation